Factors associated with virological failure in a cohort of combination antiretroviral therapy-treated patients managed at a tertiary referral centre
Raymond Fong A C , Allen C. Cheng A B , Olga Vujovic A B and Jennifer F. Hoy A B D
+ Author Affiliations
- Author Affiliations
A Department of Infectious Diseases, The Alfred Hospital, Melbourne, Vic. 3004, Australia.
B Department of Infectious Diseases, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, Vic. 3004, Australia.
C Changi General Hospital, Singapore.
D Corresponding author. Email: Jennifer.Hoy@monash.edu
Sexual Health 10(5) 442-447 https://doi.org/10.1071/SH13043
Submitted: 30 March 2013 Accepted: 1 August 2013 Published: 14 October 2013
Abstract
Background: Recent antiretroviral regimens are potent and better tolerated, resulting in a low prevalence of treatment failure. It is important to identify the drivers of virological failure, so that patients at risk can be identified early and prevention strategies implemented. Methods: We performed a retrospective case–control study of HIV-positive patients on antiretroviral therapy and managed at The Alfred Hospital during 2010 to evaluate the predictors of virological failure. Controls were matched 3 : 1 to cases by gender, and by clinical review in the same week as the diagnosis of virological failure in the case. Predictors of virological failure were identified by multivariate conditional logistic regression. Results: Thirty-nine patients were identified with treatment failure. In the multivariate model, characteristics associated with virological failure were missed clinic appointments in 1 year before virological failure (odds ratio (OR) = 13.1, 95% confidence interval (CI): 2.8–61.1), multiple previous combined antiretroviral therapy regimens (OR = 4.2, 95% CI:1.2–15.3), current hepatitis C infection (OR = 8.6, 95% CI: 1.9–38.7), older age at HIV diagnosis (OR = 1.1, 95% CI: 1.0–1.2), younger age at time of virological failure (OR = 0.9, 95% CI: 0.8 to 1.0), and CD4 cell count at virological failure (OR = 0.7, 95% CI: 0.5 to 0.9). Conclusions: Targeted and appropriate adherence support should be provided to treatment-experienced patients, particularly those who have missed clinical appointments and those with hepatitis C coinfection. Further elucidation of the barriers to clinic attendance may optimise linkage and retention in care.
Additional keywords: adherence, HIV, treatment failure.
References
[1] Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338 853–60.| Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.Crossref | GoogleScholarGoogle Scholar | 9516219PubMed |
[2] Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, et al Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006; 42 252–9.
| Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.Crossref | GoogleScholarGoogle Scholar | 16355337PubMed |
[3] Boileau C, Nguyen VK, Sylla M, Machouf N, Chamberland A, Traore HA, et al Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali. J Acquir Immune Defic Syndr 2008; 48 476–84.
| Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXosFSnsrc%3D&md5=2247a1ea1f4e6960340b7d2278a840d7CAS | 18614917PubMed |
[4] Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr 2005; 40 324–8.
| Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil.Crossref | GoogleScholarGoogle Scholar | 16249707PubMed |
[5] Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, et al Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19 1081–9.
| Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.Crossref | GoogleScholarGoogle Scholar | 15958840PubMed |
[6] Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, et al Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364 51–62.
| Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.Crossref | GoogleScholarGoogle Scholar | 15234856PubMed |
[7] Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, et al Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009; 49 1582–90.
| Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.Crossref | GoogleScholarGoogle Scholar | 19845473PubMed |
[8] Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, et al Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007; 36 294–301.
| Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).Crossref | GoogleScholarGoogle Scholar | 17213214PubMed |
[9] Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, et al Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006; 166 521–8.
| Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28Xjt1Krs70%3D&md5=5608ee6d361e447cc6459e0f4d70efdfCAS | 16534038PubMed |
[10] Robbins GK, Johnson KL, Chang Y, Jackson KE, Sax PE, Meigs JB, et al Predicting virologic failure in an HIV clinic. Clin Infect Dis 2010; 50 779–86.
| 20121574PubMed |
[11] Taylor-Castillo L, Herrera-Martinez G, Leon-Bratti MP, Boza R, Leon-Rodriguez B, Luftig RB, et al Study of antiretroviral mutants in HIV patients with treatment failures and the effect of risk factors in the virological failures. Rev Inst Med Trop Sao Paulo 2005; 47 327–31.
| Study of antiretroviral mutants in HIV patients with treatment failures and the effect of risk factors in the virological failures.Crossref | GoogleScholarGoogle Scholar | 16553322PubMed |
[12] Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B, et al Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38 1311–6.
| Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2cXksFersL8%3D&md5=3e89707bd77671dbad0e7e845c29d5ecCAS | 15127346PubMed |
[13] Knobel H, Guelar A, Carmona A, Espona M, Gonzalez A, Lopez-Colomes JL, et al Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDS 2001; 15 193–9.
| Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3M3nt1GjsA%3D%3D&md5=ee9e8e7c68f7dbcf262dc4f350eff214CAS | 11359661PubMed |
[14] Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, et al Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000; 160 1123–32.
| Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3c3kvVCltQ%3D%3D&md5=f6738d8bd1fa8eefaf827a027c6a1cf2CAS | 10789605PubMed |
[15] Míguez MJ, Lewis JE, Bryant VE, Rosenberg R, Burbano X, Fishman J, et al Low cholesterol? Don’t brag yet.. hypocholesterolemia blunts HAART effectiveness: a longitudinal study. J Int AIDS Soc 2010; 13 25
| Low cholesterol? Don’t brag yet.. hypocholesterolemia blunts HAART effectiveness: a longitudinal study.Crossref | GoogleScholarGoogle Scholar | 20626901PubMed |
[16] Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, Le Tiec C, et al Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis 2009; 9 81
| Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.Crossref | GoogleScholarGoogle Scholar | 19493344PubMed |
[17] Tsuchiya N, Pathipvanich P, Yasuda T, Mukoyama Y, Rojanawiwat A, Matsubayashi T, et al Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand. Southeast Asian J Trop Med Public Health 2009; 40 71–82.
| 19323037PubMed |
[18] Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, Freedberg KA. Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr 2007; 44 30–7.
| Predictors of antiretroviral treatment failure in an urban HIV clinic.Crossref | GoogleScholarGoogle Scholar | 17106280PubMed |
[19] Aitchison SJ, Watson KM, McCartney LM, Matthew R, Hoy J, eds. HIV Demographics in a single clinic: continued room for improvement. Australasian HIV/AIDS Conference; 2012 October 17–19; Melbourne, Australia. Sydney: Australasian Society for HIV Medicine.
[20] Bloch M, Farris M, Tilden D, Gowers A, Cunningham N. Triple-class HIV antiretroviral therapy failure in an Australian primary care setting. Sex Health 2010; 7 17–24.
| Triple-class HIV antiretroviral therapy failure in an Australian primary care setting.Crossref | GoogleScholarGoogle Scholar | 20152091PubMed |
[21] Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, Zhao Y, et al Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 2010; 50 264–71.
| Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China.Crossref | GoogleScholarGoogle Scholar | 20017637PubMed |
[22] Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, et al Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d’Ivoire. AIDS 2003; 17 S5–15.
| Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d’Ivoire.Crossref | GoogleScholarGoogle Scholar | 14565604PubMed |
[23] Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, Nash D, et al Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 2007; 45 52–9.
| Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.Crossref | GoogleScholarGoogle Scholar | 17460471PubMed |
[24] Fielding KL, Charalambous S, Stenson AL, Pemba LF, Martin DJ, Wood R, et al Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis 2008; 8 93
| Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study.Crossref | GoogleScholarGoogle Scholar | 18631397PubMed |
[25] Bedelu M, Ford N, Hilderbrand K, Reuter H. Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 2007; 196 S464–8.
| Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care.Crossref | GoogleScholarGoogle Scholar | 18181695PubMed |
[26] Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 2002; 31 S103–6.
| Measurement of adherence to antiretroviral medications.Crossref | GoogleScholarGoogle Scholar | 12562030PubMed |
[27] Hecht FM. Measuring HIV treatment adherence in clinical practice. AIDS Clin Care 1998; 10 57–9.
| 1:STN:280:DC%2BD3M3ot1aqsg%3D%3D&md5=1cfc6362b389f5be6efa182d4f8d1591CAS | 11365682PubMed |
[28] Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr 2006; 43 S79–87.
| Practical and conceptual challenges in measuring antiretroviral adherence.Crossref | GoogleScholarGoogle Scholar | 17133207PubMed |
[29] Mugavero MJ, Lin HY, Allison JJ, Giordano TP, Willig JH, Raper JL, et al Racial disparities in HIV virologic failure: do missed visits matter? J Acquir Immune Defic Syndr 2009; 50 100–8.
| Racial disparities in HIV virologic failure: do missed visits matter?Crossref | GoogleScholarGoogle Scholar | 19295340PubMed |
[30] Catz SL, McClure JB, Jones GN, Brantley PJ. Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care 1999; 11 361–73.
| Predictors of outpatient medical appointment attendance among persons with HIV.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK1MvgtlyrsA%3D%3D&md5=8e5dd40287d855424f867a4070f28f7bCAS | 10474634PubMed |
[31] Giordano TP, Gifford AL, White AC, Suarez-Almazor ME, Rabeneck L, Hartman C, et al Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 2007; 44 1493–9.
| Retention in care: a challenge to survival with HIV infection.Crossref | GoogleScholarGoogle Scholar | 17479948PubMed |
[32] Mugavero MJ, Lin HY, Willig JH, Westfall AO, Ulett KB, Routman JS, et al Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 2009; 48 248–56.
| Missed visits and mortality among patients establishing initial outpatient HIV treatment.Crossref | GoogleScholarGoogle Scholar | 19072715PubMed |
[33] Pulido F, Hill A, van Delft Y, Moecklinghoff C. Impact of hepatitis C co-infection on response to antiretroviral treatment. AIDS Rev 2012; 14 124–31.
| 22627608PubMed |
[34] Ballif M, Ledergerber B, Battegay M, Cavassini M, Bernasconi E, Schmid P, et al Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS ONE 2009; 4 e8275
| Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.Crossref | GoogleScholarGoogle Scholar | 20011544PubMed |
[35] Grimes RM, Otiniano ME, Rodriguez-Barradas MC, Lai D. Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis 2002; 34 1530–3.
| Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 12015701PubMed |
[36] Miller LG, Liu H, Hays RD, Golin CE, Beck CK, Asch SM, et al How well do clinicians estimate patients’ adherence to combination antiretroviral therapy? J Gen Intern Med 2002; 17 1–11.
| How well do clinicians estimate patients’ adherence to combination antiretroviral therapy?Crossref | GoogleScholarGoogle Scholar | 11903770PubMed |
[37] Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360 119–29.
| Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.Crossref | GoogleScholarGoogle Scholar | 12126821PubMed |
[38] Tumbarello M, Rabagliati R, de Gaetano Donati K, Bertagnolio S, Montuori E, Tamburrini E, et al Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2004; 4 46
| Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 15530169PubMed |
[39] Mayer KH. Introduction: linkage, engagement, and retention in HIV care: essential for optimal individual- and community-level outcomes in the era of highly active antiretroviral therapy. Clin Infect Dis 2011; 52 S205–7.
| Introduction: linkage, engagement, and retention in HIV care: essential for optimal individual- and community-level outcomes in the era of highly active antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 21342908PubMed |
